Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Sanofi, Sanofi en nog eens Sanofi
Volgen
TraderRon schreef:
En daarbij dan nog deze lijn.
"Acambis had a much less developed pipeline and smaller
marketshare in vaccines than Crucell"
Daarnaast zie je 2.5 miljard al steeds meer als een mogelijke prijs opduiken.
Nu nog een daadwerkelijk bod.
Er staat ook een verwachte kaspositie in die ze van Crucell verwachten. Dat zal dus uit de jaarcijfers duidelijk worden. Tot dan geen overname.
TraderRon schreef:
En daarbij dan nog deze lijn.
"Acambis had a much less developed pipeline and smaller
marketshare in vaccines than Crucell"
Daarnaast zie je 2.5 miljard al steeds meer als een mogelijke prijs opduiken.
Nu nog een daadwerkelijk bod.
Als de cijfers tegenvallen dan gaat het feest (voorlopig) niet door. Dat is mijn opinie. En dan duikt de beurskoers ook weer naar beneden.
Sander040 schreef:
[quote=TraderRon]
En daarbij dan nog deze lijn.
"Acambis had a much less developed pipeline and smaller
marketshare in vaccines than Crucell"
Daarnaast zie je 2.5 miljard al steeds meer als een mogelijke prijs opduiken.
Nu nog een daadwerkelijk bod.
[/quote]
Er staat ook een verwachte kaspositie in die ze van Crucell verwachten. Dat zal dus uit de jaarcijfers duidelijk worden. Tot dan geen overname.
Die kaspositie kun je zelf ook wel bij banadering uitrekenen. Waaruit trek je nu de conclusie dat er wel of niet een overname komt tot de jaarcijfers. Wiskundige beredenering?
Als ze een bod doen mogen ze gewoon in de boekjes kijken. Dat had Wyeth ook al gedaan en stond op een punt van rond te komen volgens de geruchten waarna ze teruggefloten werden door Pfizer. Daarvoor hoeven ze echt niet op die jaarcijfers te wachten.
Sander040 schreef:
[quote=TraderRon]
En daarbij dan nog deze lijn.
"Acambis had a much less developed pipeline and smaller
marketshare in vaccines than Crucell"
Daarnaast zie je 2.5 miljard al steeds meer als een mogelijke prijs opduiken.
Nu nog een daadwerkelijk bod.
[/quote]
Als de cijfers tegenvallen dan gaat het feest (voorlopig) niet door. Dat is mijn opinie. En dan duikt de beurskoers ook weer naar beneden.
Ik zie alleen maar negatieve ondertoon in jouw postings. "Als dit tegenvalt dan gaat de koers omlaag", "We dalen in de US", etcetra. Wil je nog 2 aandelen bijkopen tegen een lagere koers?
Sander040 schreef:
[quote=TraderRon]
En daarbij dan nog deze lijn.
"Acambis had a much less developed pipeline and smaller
marketshare in vaccines than Crucell"
Daarnaast zie je 2.5 miljard al steeds meer als een mogelijke prijs opduiken.
Nu nog een daadwerkelijk bod.
[/quote]
Er staat ook een verwachte kaspositie in die ze van Crucell verwachten. Dat zal dus uit de jaarcijfers duidelijk worden. Tot dan geen overname.
Nee, A: het staat er. Omdat die winst nog bescheiden en pril is, was het bod van Wyeth niet voor niets aan de schamele kant. Als de cijfers nu beter dan verwacht zijn of sterker..jaaaaa dan neemt ook de waarschijnlijkheid toe dat men -zij het voor minstens de KT- winstgevend is. Dan is kopen interessant! Dit DENK ik. B: bedrijfseconomische benadering: winstgevendheid betekent dat een onderneming intern kan financieren, geen beroep hoeft te doen op kapitaalaanvragen (EV/VV-financiering). Dit verhoogt de wpa en verdient daarmee de investering makkelijker terug.
gogogoo schreef:
[quote=Sander040]
[quote=TraderRon]
En daarbij dan nog deze lijn.
"Acambis had a much less developed pipeline and smaller
marketshare in vaccines than Crucell"
Daarnaast zie je 2.5 miljard al steeds meer als een mogelijke prijs opduiken.
Nu nog een daadwerkelijk bod.
[/quote]
Als de cijfers tegenvallen dan gaat het feest (voorlopig) niet door. Dat is mijn opinie. En dan duikt de beurskoers ook weer naar beneden.
[/quote]
Ik zie alleen maar negatieve ondertoon in jouw postings. "Als dit tegenvalt dan gaat de koers omlaag", "We dalen in de US", etcetra. Wil je nog 2 aandelen bijkopen tegen een lagere koers?
Zo bedoel ik het niet, sorry: maar de verwachtingen (Van dit forum) zijn hoog. Dat het dan kan tegenvallen lijkt me behoorlijk. Ok, ik ken niet de ins-and outs v Crucell, dus misschien ben ik kort door de bocht. sorry dan.
Last Trade: 19.68 Trade Time: 2:42pm ET Change: Up 0.64 (+3.36%)
Blondie@home schreef:
Last Trade: 19.68
Trade Time: 2:42pm ET
Change: Up 0.64 (+3.36%)
$20 zou lekker zijn, staan we morgen op E15.50. Zou dat lukken?
Sander040 schreef:
Nee, A: het staat er. Omdat die winst nog bescheiden en pril is, was het bod van Wyeth niet voor niets aan de schamele kant. Als de cijfers nu beter dan verwacht zijn of sterker..jaaaaa dan neemt ook de waarschijnlijkheid toe dat men -zij het voor minstens de KT- winstgevend is. Dan is kopen interessant!
Dit DENK ik.
B: bedrijfseconomische benadering: winstgevendheid betekent dat een onderneming intern kan financieren, geen beroep hoeft te doen op kapitaalaanvragen (EV/VV-financiering). Dit verhoogt de wpa en verdient daarmee de investering makkelijker terug.
niemand weet wat het bod van Wyeth precies was enige dat gezegd is was een bod met een 2 ervoor. Kan 2 miljard geweest zijn 21 euro, 29 euro. Daarnaast betaal je in deze sector niet echt voor de huidge inkomsten veel bedrijven worden opgekocht voordat ze ooit winst maken. het is geen AEGON met een simpele inkomsten/uitgaven aftrek sommetje Je betaald mede voor de potentie en de pipeline van een bedrijf en in het geval van crucell ook nog voor een productieplatform.
Nee ze zullen zo'n beetje op onze slotkoers sluiten. maar de trend is misschien wel gezet
Koerssurfer schreef:
ftalphaville.ft.com/blog/2009/01/08/5... Conclusion & Action: We believe that a possible take over of the...etc.
Dit alles is van Marcel M. en Huub V. -> SNS SNS Research Morning Note 08-01-09 Crucell (Buy): Crucell in take over talks with Wyeth The facts: Yesterday after trading the company announced that it is in discussion with Wyeth to be acquired. The WSJ indicates a take over price of USD 1.35bn. Our analysis: Crucell announced that the merger/acquisition talks are still in a preliminary stage. Wyeth is one of Crucell's key partners in the development of vaccines on its PER.C6 cell line. Since July 2007, Wyeth has an exclusive license on using Crucell's platform technology PER.C6 for the development of an undisclosed vaccine. In the area of vaccines, Wyeth is developing vaccines for viral and bacterial infections like HIV. Only yesterday, Wyeth's CEO indicated that the company is looking for acquisitions in the biotech sector. The pharmaceutical company has a cash position of more than USD 14bn. In 2007, Wyeth generated sales in total of USD 22.4bn. Conclusion & Action: We believe that a possible take over of the company is surprising at the current stage. The company has enough resources and growth potential to continue independently. We therefore think that the suggested take over price of USD 1.35bn (USD 20.50 or EUR 15.20 per share) is only a first offer in negotiations and is clearly below our already conservative valuation of the company. Considering a take over bid, we believe that a price per share of EUR 22.50-25 would be more jusitified. In that case the full potential of its technologies, its products and pipeline is taken into account. Recent acquisitions of mid sized to small biotech companies in Europe by pharma companies showed take over premiums of 50-90%. Last year, vaccine producer Acambis was bought by Sanofi Aventis with a premium of 65% on its share price. Acambis had a much less developed pipeline and smaller marketshare in vaccines than Crucell. We expect Crucell to become profitable as of this year with an estimated cash level of around EUR 170m (USD 230m). We think that the take over talks also could trigger other pharmaceutical companies like Novartis and Sanofi Aventis to consider a talk over bid. Both companies are important partners of Crucell. SNS Research Morning Note 26-01-09 Crucell (Buy): Take over talks with Wyeth discontinued The facts: Crucell announced that Wyeth has withdrawn from discussions regarding a possible talk over of the company. Our analysis: No additional news was issued by Crucell. Conclusion & Action: For the short term the withdrawal of Wyeth from the take over discussion is negative for the share price. We expect the price to react negatively to this. Although there was no comment from both parties about the reason to stop the talks, we think that the value of a potential bid was the issue. A suggested offer of USD 1.35bn or EUR 15.50 per share was believed to be far too low. The possible take over of Wyeth by Pfizer might also be a factor, although we believe that these talk over talks already have been going on before Wyeth started its negotiations with Crucell. Fundamentally, we do not believe that this should affect the potential value of the company. Crucell is perfectly capable to continue independently. Its cashlevel is expected to be around EUR 170m by the end of 2008 and the company is expected to become profitable for the whole of 2009. Still, we definitely do not rule out a possible bid by another pharmaceutical company. It that respect both Crucell's strategic partners Novartis and Sanofi Aventis can be mentioned. Fact remains that Crucell is a take over candidate and that management is open for discussions, considering that the right price will be paid. We maintain our Buy rating. Flash note 8 January 2009 Let the bidding begin Yesterday, Crucell announced that is it preliminary talks with Wyeth about a take over of the company. Wyeth is already an important partner of Crucell in the development of vaccines using Crucell’s PER.C6 technology. It is believed that Wyeth wants to offer USD1.35bn for the company. In our view this is only a first offer that could trigger the interest of other pharmaceutical companies as well. We believe a higher price to be validated. As one of the few larger still independent vaccine companies left, Crucell is named as a possible take over candidate for some time. However, the timing comes for us as a surprise. The company is on the brink of becoming profitable and has a strong balance sheet with an estimated cash level of more than EUR 170m. Its main vaccine Quinvaxem already was awarded contracts by Unicef and other supranational organisations of up to USD 500m till the end of 2009 and is increasingly profitable. Also with the development of its vaccines against infectious diseases like influenza, tuberculosis and malaria, the company has made good progress. We therefore believe that Crucell is perfectly capable to continue independently. This should give management a strong negotiation position. Nevertheless, we think that with take over talks started, it will be difficult for Crucell to maintain its independent position. Wyeth is one of Crucell’s most important partners and also a global Top-5 player in the vaccine market. The negotiations will probably attract the interest of other key partners of Crucell as well, being Sanofi Aventis and Novartis. With both companies Crucell has partnerships on important products in Crucell’s portfolio. Also Sanofi and Novartis belong to the Top-5 vaccine players. Especially Sanofi should gain from a take over of Crucell as it partners key products like Crucell’s influenza vaccine and the antibody cocktail against rabies. Both products are developed on Crucell’s unique human cell line PER.C6. This cell line is well on its way to become an industry standard for the more efficient production of vaccines and proteins. Next to that, all important vaccine players including Wyeth, Novartis and Sanofi have said that they seek acquistions to strengthen their position in vaccines.
In all, we believe that with the take over talks with Wyeth, the bidding process for Crucell only started. Considering prices that have been paid sofar for late stage biotech companie and our underlying valuation of Crucell, we think that the company has a considerably higher value than the suggested offer of USD 1.35bn. We advice investors to hold on to their stock as a higher price is definitely feasible. We reiterate our BUY recommendation. Product Stage Market Growth Price per Peak Royalty/ Discount Valuation R patients patient Market share Margin factor EUR (m) Quinvaxem Market 50 million 10% + 3.2 40% 35% 10% 300-350m Dukoral Market 10 million 5% 10 10% 35% 10% 15-20m Vivotif Market 10 million 5% 10 10% 35% 10% 15-20m Inflexal Market 20 million + 5% 10 5% 30% 10% 20-25m Hepaxal Market 20 million + 3% 15 5% 30% 10% 20-25m Influenza vaccine Phase II 1 billion 15% 5 40% 10% 18% 350-400m Ebola vaccine Phase I 4 million 2% 10 100% 50% 20% 20-25m TB vaccine Phase I 50 million + 5% 5 25% 35% 18% 40-50m Rabies antibody Phase II 50 million 5% 30 40% 20% 18% 80-100m Malaria vaccine Phase I 100 million + 10% 4 25% 25% 20% 60-80m HIV vaccine Phase I 100 million + 3% 500 20% 40% 25% 20-40m PER C6 Technology EUR 10bn+ 10% 50-250k 15% 2.5% 350-400m STAR Technology EUR 10bn+ 10% 250k 10% 2.5% 50-80m Total 1340-1615m Cash 170m 1510-1785mwww.iex.nl/forum/topic.asp?forum=228&...
Sanofi seen chasing mid-sized acquisitions Tue Feb 3, 2009 8:01am EST By Noelle Mennella PARIS (Reuters) - Facing the loss of patents, Sanofi-Aventis (SASY.PA) will have to makes acquisitions in 2009 to boost its growth, say analysts, who predict the French pharmaceuticals group will target medium-sized companies. A mega-deal along the lines of Pfizer's (PFE.N) planned $68 billion purchase of Wyeth (WYE.N) is much less likely, at least for now, than an acquisition of something a bit smaller such as vaccine maker Crucell (CRCL.AS). Bolt-on acquisitions would have a quicker and more visible impact than the restructuring of Sanofi's production sites or the reorganization of its research activities, two tasks which are also on new Chief Executive Chris Viehbacher's "to-do" list. Viehbacher, a former GlaxoSmithKline (GSK.L) executive, took the helm of Sanofi in December after big shareholders Total (TOTF.PA) and L'Oreal (OREP.PA) pushed for a change at the top of the world's third-largest drugmaker to reinvigorate its performance. He is expected to use M&A to accelerate the company's growth after recent moves by Sanofi to acquire vaccines maker Acambis and Czech generic drug group Zentiva (ZNTVsp.PR). Last week, Viehbacher told staff Sanofi "had to grow", using the 4 billion euros ($5.1 billion) it generates annually in free cash flow. He is likely to detail this strategy on February 11, the day Sanofi unveils full-year 2008 results. Sanofi is in dire need of new blockbuster medicines that can help compensate for sales losses of older drugs due to generic competition and to new branded rivals. "Chris Viehbacher's strategy is to redeploy the group's activity on growth segments and Sanofi's strong points are vaccines, emerging countries and (consumer) healthcare products. This will be made partly through acquisitions," Natixis analyst Philippe Lanone said. Sanofi will likely target one or more medium-sized deals to re-energise sales growth, Lanone added. Eric Le Berrigaud, analyst at Raymond James Euro Equities, ruled out a "mega-acquisition", such as Pfizer's move on Wyeth. BRISTOL-MYERS TALK There has been persistent speculation in the past that Sanofi might acquire its U.S. partner Bristol-Myers Squibb (BMY.N), with which it markets the blockbuster blood-thinning drug Plavix. But making a play for Bristol, which has market value of around $42 billion, would probably be a step too far for Viehbacher so soon after becoming CEO. "Our belief is that Mr Viehbacher is too new to the job to make an immediate run for Bristol-Myers Squibb," Tim Anderson of Sanford Bernstein said. In addition, with both Pfizer and Roche (ROG.VX) currently in the market for funding to buy Wyeth and Genentech (DNA.N) respectively, there might not be enough funds to go around to allow a third big pharma deal, he added. Crucell, a Dutch vaccine maker with a market capitalization of around 1 billion euros ($1.3 billion), which had been in merger talks with Wyeth before the Pfizer deal, is considered by analysts a more manageable target. "Sanofi would be a natural acquirer of the company (Crucell), all the more so now that everyone is trying to grow through vaccines, where few targets are available," Le Berrigaud said. Another analyst, who asked not to be identified, said Viehbacher would do at Sanofi "what he did at GSK -- acquire small and medium biotechnology companies," with market capitalizations of up to 5 billion euros. "Banks should easily go along with that," the analyst added. Last week, Viehbacher told employees he was looking into "ways of diversifying the group in terms of OTC (over the counter) medicines, vaccines and perhaps other healthcare products." He also said he wanted to expand oncology activities and boost the group's biotech business. But Sanofi will probably have to make choices in its portfolio of products and this may lead to a reduction in the number of its production sites, analysts said. "Cost cutting is not officially on the agenda but Sanofi will accentuate it. Chris Viehbacher will not say it but he will do it as soon as he has renewed the group's management ... he has no other choice," said one analyst, speaking on condition of anonymity. (Additional reporting by Ben Hirschler in London; writing by Marie Maitre; Editing by Hans Peters)www.reuters.com/article/companyNews/i...
sec.edgar-online.com/sanofi-aventis/2... Misschien dat iemand hier wat aan heeft? Volgens mij moet je registreren voor deze gegevens maar met de link lukt het ook. Voor iemand die zich snel wil verdiepen in Sanofi-aventis die zal daar genoeg informatie vinden.
He (viehbacher of Sanofi) is likely to detail this strategy on February 11, the day Sanofi unveils full-year 2008 results. Als hij dan toch daar iets wil zeggen dan kan hij beter voor die datum iets doen. Komt net even energieker over. Mocht hij Crucell noemen, dan is dat leuk. Als hij een bod doet, dan hoop ik wel dat niemand daar op ingaat. Het blijft IMHO voor Crucell aandeelhouders nog een paar jaar te vroeg.
FEBRUARY 3, 2009, 3:55 P.M. ET (WSJ) Those that appear open to large combinations include Merck & Co. (MRK) and Sanofi-Aventis (SNY), although not necessarily with each other. Merck Chief Executive Richard Clark said Tuesday that he was open to "the entire spectrum" of transactions, including a large-scale deal. Clark previously expressed interest in acquiring a biotechnology company Nu is de vraag: Merck & Co i.p.v.Sanofi?
Pharmaceutical Companies - Cash Available*: Merck & Co: ~$ 10.00 billion Net iets meer op de plank liggen dan Sanofi ....
sempre avanti schreef:
Pharmaceutical Companies - Cash Available*:
Merck & Co: ~$ 10.00 billion
Net iets meer op de plank liggen dan Sanofi ....
Wie is de volgende in jouw glazen bol na Merck. Leuk voor een pooltje.
European Commission Clears Acquisition of Zentiva NV by sanofi-aventis 04 Feb 2009 - Offer of CZK 1150 in Cash per Share Represents a 25.5% Premium to April 30, 2008 Closing Share Price and Has Been Recommended by Zentiva Board of Directors - - Zentiva Shareholders Have Until February 20, 2009 To Tender Shares - Paris, France Paris, France – February 4, 2009 - Sanofi-aventis announced today that the European Commission has granted competition law clearance to the proposed acquisition of Zentiva NV (Zentiva) by sanofi-aventis Europe. Sanofi-aventis welcomes this decision, which will allow the Offer to proceed. The offer expiration date is maintained at February 20, 2009. The Offer remains subject to a minimum tender condition of 10,339,203 shares, which is designed to ensure that after the Offer sanofi-aventis Europe would hold more than half of Zentiva’s fully diluted share capital and voting rights. If the Offer is successful, sanofi-aventis Europe intends to terminate Zentiva’s listings on the London and Prague Stock Exchanges as soon as possible. Furthermore, subject to the necessary threshold being reached, sanofi-aventis Europe expects to initiate the statutory squeeze-out procedure contemplated by the Dutch Civil Code in order to acquire all shares held by minority shareholders. Sanofi-aventis is committed to the expansion of its presence into emerging markets that are characterised by high growth, low and medium disposable income and affordable pharmaceutical products. Sanofi-aventis believes that Zentiva will constitute an exceptional opportunity to accelerate this strategy and intends that Zentiva becomes a platform for further growth in the Central and Eastern European (CEE) markets. In connection with the European Commission competition law clearance, sanofi-aventis has agreed to divest products from both groups in a limited number of CEE markets. The divested products collectively generate annual sales of approximately €18 million in 2007, an amount which is less than 3% of Zentiva’s consolidated sales for that year. Sanofi-aventis Europe has made certain commitments to Zentiva with respect to the treatment of Zentiva employees. The parties intend for Mr Jiri Michal to continue as CEO and executive director of Zentiva following the closing of the Offer. ...en.sanofi-aventis.com/binaries/200902...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
910,33
-0,34%
EUR/USD
1,0876
-0,08%
FTSE 100
8.412,96
-0,39%
Germany40^
18.851,30
-0,10%
Gold spot
2.391,35
+0,20%
NY-Nasdaq Composite
16.742,39
+1,40%
Stijgers
Dalers